Glaxo failed to warn of diabetes drug risk

The widow and son of a Texas man who was taking a GlaxoSmithKline Plc diabetes drug at the time of his fatal Heart attack claims the drugmaker failed to warn about the drug’s risks, according to a lawsuit.

The claim involves rosiglitazone, which is sold under the brand names Avandia and Advandamet. Investors have been bracing for a flood of litigation against Glaxo after a widely publicized medical report suggested Avandia increases the risk of Heart attack. 

The lawsuit was filed Tuesday by relatives of Larry Alan Stanford in the U.S. District Court for the Eastern District of Texas.

“Glaxo knew or should have known that its rosiglitazone drug greatly increased plaintiffs’ risks of having a Heart attack and/or other negative cardiovascular consequences or of causing sudden cardiac death,” the lawsuit said. 

Print Version
Tell-a-Friend

RELATED ARTICLES:

Hypertension Develops Early, Silently, in African-American Men   New European guidelines on heart attack management put emphasis on speed of action   More US women are surviving heart attack   Risks seen in opposite-sex heart transplants   Exercise improves quality of life for heart failure patients   Researchers present new theory that may lead to effective heart failure treatments   Obese kids’ artery plaque similar to middle-aged adults   Study Sheds Light on Participants in National SEARCH for Diabetes in Youth Study   Exercise is safe, improves outcomes for patients with heart failure   Pregnancy diabetes doubles the risk of language delay in children   Clinical Guideline on Prevention of Cardiovascular Disease and Diabetes in Patients at Highest Risk   Experts Available to Comment on New Study about Risk of Sudden Cardiac Death